(Q64188265)

English

XL888 + Vemurafenib + Cobimetinib for Unresectable BRAF Mutated Stage III/IV Melanoma

clinical trial

In more languages

edit

Statements

instance of

clinical trial

0 references

title

Phase I Study of Escalating Doses of XL888 With Vemurafenib Plus Cobimetinib for Patients With Unresectable BRAF Mutated Stage III/IV Melanoma (English)

0 references

medical condition

melanoma

0 references

country

United States of America

0 references

main subject

Stage III melanoma incidence and impact of transitioning to the 8th AJCC staging system: a US population-based study

0 references

start time

11 August 2016

0 references

end time

December 2020

0 references

number of participants

36

0 references

research intervention

vemurafenib

0 references

clinical trial phase

phase I clinical trial

0 references

minimum age

18 year

0 references

study type

interventional study

0 references

Identifiers

ClinicalTrials.gov ID

NCT02721459

0 references

(Q64188265)

XL888 + Vemurafenib + Cobimetinib for Unresectable BRAF Mutated Stage III/IV Melanoma

Statements

Identifiers

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)